Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$200.47 USD

200.47
3,531,078

-3.08 (-1.51%)

Updated Nov 4, 2024 04:00 PM ET

Pre-Market: $199.87 -0.60 (-0.30%) 8:02 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, AbbVie (ABBV) closed at $78.60, marking a -0.11% move from the previous day.

J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study

J&J's (JNJ) Tremfya meets the primary endpoint in a late stage study that evaluated the efficacy and safety of the drug for treating patients with psoriatic arthritis.

Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz

Novartis (NVS) announces positive data on CML drugs and biosimilar Hyrimoz.

Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

Top Ranked Income Stocks to Buy for June 17th

Here are four stocks with buy rank and strong income characteristics for investors to consider today, June 17th.

Zachary Stutler headshot

3 Big Pharma Stocks to Buy Right Now

These big pharma stocks all have a Zacks Rank #2 or better.

Pfizer's (PFE) Xeljanz Effective As Monotherapy in RA Study

Pfizer's (PFE) study on JAK inhibitor Xeljanz XR demonstrates the efficacy of the medicine when used as a monotherapy without methotrexate.

Roche's Polivy Gets FDA Nod, Gazyva Meets Goals in Phase II

Roche's (RHHBY) hematology portfolio gets a boost as FDA approves Polivy for DLBCL, and lymphoma drug, Gazyva, meets goals in a phase II study.

Lilly Announces Tradjenta Cardiovascular Outcome Study Data

Tradjenta leads to fewer events of hypoglycemia and modest weight reduction in type II diabetes patients compared to Sanofi's Amaryl.

AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

AbbVie (ABBV) closed at $76.95 in the latest trading session, marking a -0.62% move from the prior day.

Top Ranked Growth Stocks to Buy for June 10th

Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, June 10th

AstraZeneca's Calquence Meets Endpoint in 2nd CLL Study

AstraZeneca's (AZN) lymphoma drug, Calquence, meets the primary endpoint and a key secondary one in a phase III study for the first-line treatment of chronic lymphocytic leukaemia.

Zacks.com featured highlights include: HP, Party City, AbbVie, OncoSec Medical and Pulmatrix

Zacks.com featured highlights include: HP, Party City, AbbVie, OncoSec Medical and Pulmatrix

Sanghamitra Saha headshot

Bet on 5 Top Stocks With Rising P/E

Bet on these top-ranked stocks with rising P/E to realize outsized gains.

Top Ranked Income Stocks to Buy for June 6th

Here are three stocks with buy rank and strong income characteristics for investors to consider today, June 6th.

Pfizer to Launch Several Drugs Despite Generic Headwinds

Pfizer (PFE) looks well positioned to launch several breakthrough innovative medicines in the next five years amid loss of exclusivity headwinds.

Merck's Antibiotic Zerbaxa Gets FDA Nod for New Indication

Merck (MRK) gets FDA approval for antibacterial medicine, Zerbaxa for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP)

AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know

AbbVie (ABBV) closed at $75.84 in the latest trading session, marking a -1.13% move from the prior day.

Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

Vertex Selects Triple Combo Regimen for Regulatory Submission

Vertex (VRTX) choses VX-445 triple combination regimen for global regulatory submissions to seek approval for the regimen as a treatment for cystic fibrosis based on 24-week phase III study data.

J&J Stock Up This Year So Far: Will the Momentum Continue?

J&J (JNJ) performs better than the industry in 2019 so far and looks well poised to sustain the momentum in the rest of the year.

Glaxo's Shingles Vaccine Shingrix Gets Approval in China

GlaxoSmithKline (GSK) plans to launch Shingrix in China in several phases starting 2020.

Why Is AbbVie (ABBV) Up 0.9% Since Last Earnings Report?

AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Kinjel Shah headshot

Pharma Stock Roundup: MRK's Cancer Biotech Buyout, ABBV, LLY's Pipeline Updates

Key highlights of the week include Merck's (MRK) offer to buy private cancer biotech and AbbVie (ABBV) and Lilly's (LLY) updates from clinical studies.

J&J's Invokana sNDA Gets Priority Review Status From FDA

FDA grants priority review to J&J's (JNJ) Invokana sNDA for the treatment of chronic kidney disease in patients with type II diabetes